Radiotherapy of primary CNS lymphoma in HIV-positive and negative patients: ten years of treatment experience at UCSF (Meeting abstract).

Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

Radiotherapy of primary CNS lymphoma in HIV-positive and negative patients: ten years of treatment experience at UCSF (Meeting abstract).

American Radium Society's 75th Annual Meeting. April 24-28, 1993, Aruba, p. 23, 1993.. Unique Identifier : AIDSLINE ICDB/94698236
Ling S; Roach M; Wara W; Dept. of Radiation Oncology, UCSF, San Francisco, CA

Abstract: In a ten year retrospective review, charts of all patients treated at UCSF in the Radiation Oncology Department for primary CNS lymphoma between January 1982 and January 1992 were analyzed. In total there were fifty cases, 35 were known to be HIV+, the remaining 15 were felt to be classical nonepidemic CNS lymphoma. The median length of survival for HIV+ patients was 2 months as compared to 11 months for HIV- patients; although, the average KPS score at presentation for HIV+ patients was 50 while that of HIV- patients was 30. The average age of the HIV+ patients was 37.5 years, while that of the HIV- patients was 50.8 years. Five of the fifteen HIV- patients were female, all of the HIV+ patients were male. Forty-two patients were treated in the years 1987-1992, representing a more than five-fold increase in the incidence of primary CNS lymphoma as compared with the incidence in the preceding five year period. This increase was primarily attributed to the immunosuppression associated with the AIDS epidemic. The most commonly administered total radiotherapy dose was 40-41 Gy, with a range of 300 cGy to 72.5 Gy. We currently recommend HIV+ patients receive 4000 cGy whole-brain in 3 weeks, while HIV- patients receive 6000 cGy in 6 weeks plus multidrug chemotherapy.

Keywords: Adult Central Nervous System Neoplasms/*RADIOTHERAPY Female Human *HIV Seropositivity Lymphoma, AIDS-Related/*RADIOTHERAPY Male Middle Age Radiotherapy Dosage Retrospective Studies ABSTRACT
940430
M9440914

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .